
Targeting Lipoprotein(a): A New Frontier in Heart Disease
Heart MattersTargeting Lipoprotein(a): A New Frontier in Heart Disease

The GRADE Framework: Five Lenses for Evaluating Randomized Trial Evidence
Heart MattersThe GRADE Framework: Five Lenses for Evaluating Randomized Trial Evidence

Treating What We Can: A Practical Approach to High Lipoprotein(a)
Heart MattersTreating What We Can: A Practical Approach to High Lipoprotein(a)

Turning an Lp(a) Result into a Prevention Opportunity
Heart MattersTurning an Lp(a) Result into a Prevention Opportunity

Rethinking CKD Screening in the Era of New Therapies
Heart MattersRethinking CKD Screening in the Era of New Therapies

Who Should Be Tested for Chronic Kidney Disease?
Heart MattersWho Should Be Tested for Chronic Kidney Disease?
- advertisement
- 5 questions
- advertisement

Quick Takes in ATTR-CM: Diagnosis Barriers
Medical Industry FeatureQuick Takes in ATTR-CM: Diagnosis Barriers

Single-Port Robotics Improves Outcomes for Thoracic Surgery
Medical Industry FeatureSingle-Port Robotics Improves Outcomes for Thoracic Surgery

Helping Patients Stay on Track With Collaborative LDL-C Care
Medical Industry FeatureHelping Patients Stay on Track With Collaborative LDL-C Care

Beyond the Flu: Safeguarding Older Adults Through Vaccination
VacciNationBeyond the Flu: Safeguarding Older Adults Through Vaccination

Not Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Conversations in CV Risk AssessmentNot Just for Diabetes: Broadening uACR Screening to CV Risk Populations

Unseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Conversations in CV Risk AssessmentUnseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
- 11/09/2026
- 11/09/2026
- 11/09/2026
- 11/09/2026
- 11/09/2026
- 11/03/2026















































